Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.

Publications

Ranbaxy Revisited: Rejecting the Performance-based Approach to No-injury Class Actions?

August 2019 - DRI's For The Defense

Publications

Ranbaxy Revisited: Rejecting the Performance-based Approach to No-injury Class Actions?

August 2019 - DRI's For The Defense

One of the basic principles of federal law is that under Article III, one must suffer an injury to have standing to sue. Therefore, when consumers purchase a drug, it performs as intended, and then they turn around and bring a class action against the manufacturer, “something is rotten in the state of [New Jersey].” W. Shakespeare, Hamlet, Prince of Denmark, act 1, scene 4, line 90. Yet “no-injury” class actions are increasingly common, and members of the plaintiffs’ bar prepare to file class action lawsuits the moment that a recall of a prescription drug is announced.

Read the article here.

Related News

Insight From the Inside

Karen E. Ross, published in OACTA Quarterly Review More